CAR-NK-92MI and CAR-CD19-T cells targeting CD19 antigen exhibit significant in vitro killing activity on mantle cell lymphoma
10.3872/j.issn.1007-385x.2018.05.003
- VernacularTitle:靶向CD19抗原的CAR-NK-92MI和CAR-CD19-T细胞对套细胞淋巴瘤 的体外杀伤
- Author:
ZHAO Songbo
1
;
HAN Zhichao
1
;
AN Gangli
1
;
MENG Huimin
1
;
YANG Lin
1
Author Information
1. (The Cyrus Tang Hematology Center, Soochow University, Suzhou, 215000, Jiangsu, China
- Publication Type:Journal Article
- Keywords:
mantle cell lymphoma;
CAR-NK-92MI cell;
CAR-CD19-T cell
- From:
Chinese Journal of Cancer Biotherapy
2018;25(5):455-461
- CountryChina
- Language:Chinese
-
Abstract:
[Abstract] Objective: To investigate the in vitro cytotoxicity of the chimeric antigen receptor-modified T cells and NK-92MI cells (CAR-NK-92MI cells) and CAR-CD19-T cells against mantle cell lymphoma (MCL). Methods: CAR-T cell technology, successfully obtained in clinical trial of B-lineage acute lymphoblastic leukemia (B-ALL) treatment, was used in this study. In the case of high expression of CD19 antigen in MCL, CAR- CD19-T cells and CAR- CD19-NK-92MI cells targeting CD19 antigen were generated, respectively. Then, their cytotoxicity against MCL cell lines was detected by LDH release assay and the results were verified by flow cytometry. Results: Compared with control group, both CAR-NK-92MI and CAR-CD19-T cells exhibited prominent killing effect against MCLcells（all P<0.01）; in addition, the two CAR cells exhibited high cytotoxicity against K562-CD19 cells but not on K562 cells（all P <0.01）. The death rate of MCL cells from CAR-NK-92MI group was 30%-40% more than that of control group, and the death rate of MCL from CAR-CD19-T group was 40%-50% more than that of control group. Conclusion: Both CAR-NK-92MI and CAR-CD19-T cells exhibited potent cytotoxicity against MCLcells in vitro.
- Full text:201805031.pdf
